全文获取类型
收费全文 | 3046篇 |
免费 | 117篇 |
国内免费 | 16篇 |
专业分类
耳鼻咽喉 | 16篇 |
儿科学 | 87篇 |
妇产科学 | 133篇 |
基础医学 | 209篇 |
口腔科学 | 69篇 |
临床医学 | 386篇 |
内科学 | 221篇 |
皮肤病学 | 16篇 |
神经病学 | 33篇 |
特种医学 | 192篇 |
外科学 | 340篇 |
综合类 | 95篇 |
预防医学 | 102篇 |
眼科学 | 23篇 |
药学 | 112篇 |
2篇 | |
中国医学 | 11篇 |
肿瘤学 | 1132篇 |
出版年
2024年 | 4篇 |
2023年 | 76篇 |
2022年 | 161篇 |
2021年 | 224篇 |
2020年 | 114篇 |
2019年 | 659篇 |
2018年 | 504篇 |
2017年 | 194篇 |
2016年 | 61篇 |
2015年 | 85篇 |
2014年 | 158篇 |
2013年 | 112篇 |
2012年 | 64篇 |
2011年 | 65篇 |
2010年 | 51篇 |
2009年 | 62篇 |
2008年 | 58篇 |
2007年 | 44篇 |
2006年 | 46篇 |
2005年 | 22篇 |
2004年 | 15篇 |
2003年 | 18篇 |
2002年 | 7篇 |
2001年 | 8篇 |
2000年 | 11篇 |
1999年 | 13篇 |
1998年 | 4篇 |
1997年 | 4篇 |
1996年 | 2篇 |
1995年 | 4篇 |
1994年 | 6篇 |
1993年 | 1篇 |
1992年 | 2篇 |
1990年 | 1篇 |
1989年 | 1篇 |
1988年 | 1篇 |
1985年 | 43篇 |
1984年 | 60篇 |
1983年 | 31篇 |
1982年 | 34篇 |
1981年 | 34篇 |
1980年 | 38篇 |
1979年 | 26篇 |
1978年 | 13篇 |
1977年 | 7篇 |
1976年 | 15篇 |
1975年 | 4篇 |
1974年 | 8篇 |
1973年 | 3篇 |
1970年 | 1篇 |
排序方式: 共有3179条查询结果,搜索用时 15 毫秒
81.
Georgios Chatzikonstantinou Nikolaos Zamboglou Dimos Baltas Konstantinos Ferentinos Dimitra Bon Nikolaos Tselis 《Brachytherapy》2019,18(6):829-834
PurposeTo evaluate the clinical outcome after CT-guided interstitial high-dose-rate (HDR) brachytherapy for dose escalation in the radiotherapy treatment of inoperable locally advanced non–small-cell lung cancer (NSCLC).Methods and MaterialsFrom 2005 to 2015, 16 patients with unresectable NSCLC were treated. Median age was 65.7 years (range, 52–86). The median tumor volume was 95.3 cm3 (range, 20.0–2000.0). The median prescribed HDR was 15.0 Gy (range, 7.0–32.0) delivered in twice-daily fractions of 6.0–8.0 Gy in 4 patients and in once-daily fractions of 7.0–15.0 Gy in 12 patients, respectively.ResultsAfter a median followup of 12.5 months, median overall survival and local control was 12.9 and 24.9 months, respectively. The corresponding median overall survival and local control rates at 1, 2, and 3 years were 56.2%, 37.5%, and 12.5% as well as 68.9%, 57.4%, and 43%, respectively. Apart from one Grade 1 cough episode persisting for 1 week and one patient developing a minor hemopneumothorax requiring no postprocedural drainage, no other adverse events were recorded.ConclusionsCT-guided interstitial HDR brachytherapy is a safe modality for radiation dose escalation which may play a role in the definitive radiotherapy treatment of locally advanced NSCLC. 相似文献
82.
Ting Martin Ma Matthew M. Harkenrider Catheryn M. Yashar Akila N. Viswanathan Jyoti S. Mayadev 《Brachytherapy》2019,18(3):361-369
PurposeTo understand the reasons behind current low utilization of brachytherapy for locally advanced cervical cancer in the United States.Methods and MaterialsA 17-item survey was e-mailed to the American Brachytherapy Society (ABS) listserv of active members in 2018. Responses of attending physicians in the United States were included in the analysis.ResultsAmong a total of 135 respondents, 81 completed the survey. Eighty-four percent agree/strongly agree that cervical brachytherapy is underutilized, and 46.9% disagree/strongly disagree that residents are receiving adequate training for brachytherapy; 75.3% agree/strongly agree that inadequate maintenance of brachytherapy skills is a major obstacle to brachytherapy use; and 71.6% agree/strongly agree that increased time requirement constitutes a major obstacle. Over 97% will recommend brachytherapy for most patients with cervical cancer if given access/time; 72.8% always perform their own brachytherapy, whereas 29.6% reported some type of barrier exists in performing brachytherapy themselves, with time required to perform brachytherapy (9.9%) being a leading factor. A quarter (24.7%) routinely refer to other radiation oncologists for brachytherapy. Even among ABS members, 37.0% reported that they would perform an intensity-modulated radiation therapy or stereotactic body radiation therapy boost in specific scenarios in potentially curable patients. The most common scenario is inability to place a uterine tandem (56.7%).ConclusionsThe underutilization of brachytherapy in cervical cancer is widely recognized by ABS members with inadequate training during residency and inadequate maintenance of skills being possible major contributing factors. Even among ABS members, there are identifiable barriers. Continued advocacy and future initiatives in enhancing access to brachytherapy training and efficiency are needed. 相似文献
83.
84.
Sangjune Laurence Lee Ananth Ravi Gerard Morton Andrew Loblaw Chia-Lin Tseng Masoom Haider Jure Murgic Alexandru Nicolae Mark Semple Hans T. Chung 《Brachytherapy》2019,18(5):567-573
PurposeTo explore the changes in T2-weighted (T2w) and apparent diffusion coefficient (ADC) magnetic resonance imaging -derived radiomic features of the gross tumor volume (GTV) from focal salvage high-dose-rate prostate brachytherapy (HDRB) and to correlate with clinical parameters.Materials and MethodsEligible patients included those with biopsy-confirmed local recurrence that correlated with MRI (T2w, ADC). Patients received 27 Gy in 2 fractions separated by 1 week to a quadrant consisting of the GTV. The MRI was repeated 1 year after HDRB. GTVs, planning target volumes, and normal prostate tissue control volumes were identified on the pre- and post-HDRB MRIs. Radiomic features from each GTV were extracted, and principle component analysis identified features with the highest variance.ResultsPre- and post-HDRB MRIs were obtained from 14 trial patients. Principle component analysis showed that 18 and 17 features contributed to 93% and 86% of the variance observed in the T2w and ADC data, respectively. Sixteen T2w features and 1 ADC GTV feature were different from the control volumes in the pre-HDRB images (p < 0.05). Ten T2w and 7 ADC GTV post-HDRB features were different from those of pre-HDRB (p < 0.05).ConclusionsExploratory analysis reveals several radiomic features in the T2w and ADC image GTVs that distinguish the GTV from healthy prostate tissue and change significantly after salvage HDRB. 相似文献
85.
Sylwia Kellas-Ślęczka Brygida Białas Marek Fijałkowski Piotr Wojcieszek Marta Szlag Agnieszka Cholewka Marcin Wesołowski Maciej Ślęczka Tomasz Krzysztofiak Dawid Larysz Zofia Kołosza Karolina Trzaska Agnieszka Pruefer 《Brachytherapy》2019,18(4):493-502
PURPOSETo report the outcomes for 76 patients with penile cancer treated with high-dose-rate brachytherapy (HDR-BT) at a single institution.METHODSSeventy-six patients with penile cancer treated with HDR-BT in our department between October 1998 and September 2018 were analyzed. Seventy underwent interstitial HDR-BT (fractionation dose range of 3–3.5 Gy given twice a day with an interval of at least six hours between the fractions), and six underwent superficial treatment with mold applicators (fractionation dose range of 4–7 Gy given once or twice a week).RESULTSMedian follow-up was 76 months (7–204 months). In the whole group, 22/76 local failures (28.9%) were observed: 14/76 (18.4%) local recurrences and 8/76 (10.5%) cases of persistent disease. Median time to recurrence was 24 months (9–54 months). Inguinal lymph node metastases were observed in 18/76 cases (23.7%). Distant metastases occurred in 12/76 (15.8%) cases. Patients with local recurrence and persistent disease underwent salvage penectomies, except four who refused surgery and underwent a second course of interstitial HDR-BT. Five- and 10-year cause-specific survival were 85.0% and 77.8%, respectively. Local control at 5 and 10 years was 65.6%. Five- and 10-year penile preservation were 69.5% and 66.9%, respectively. There was no G3 or G4 acute toxicity. One urethral stenosis (1.3%) occurred in a patient with a T3 tumor and was treated successfully with dilatation.CONCLUSIONSHDR-BT provides good local control of penile cancer and is a good option for penis preservation therapy and in our experience achieves a penile preservation rate at 10 years of 66.9%. 相似文献
86.
87.
“There is always a better way”: Managing uncertainty in decision making about new cancer drugs in Canada
下载免费PDF全文
![点击此处可从《The International journal of health planning and management》网站下载免费的PDF全文](/ch/ext_images/free.gif)
S. Michelle Driedger Elizabeth Cooper Gary Annable Melissa Brouwers 《The International journal of health planning and management》2018,33(2):e485-e499
Policy decisions about the approval and funding of new cancer drugs must often be made in an environment of complex uncertainty about clinical and cost‐effectiveness data. The focus of this article is on the results from qualitative interviews with senior officials (n = 16) who make decisions about or influence cancer drug policy in various organizations in the Canadian cancer control system. Most participants identified the use of a limited number of informal approaches to address uncertainty, such as grounding decisions in evidence and advice from expert groups. People tended to focus on evidence informed decisions including price negotiations, the ability to implement policy changes, and stakeholder values. Lessons from the Canadian context related to continuing efforts to build a public culture of understanding into how policy decisions like cancer drug funding are made may result in greater acceptance and increased confidence in health policy decision‐making processes across multiple sectors internationally. 相似文献
88.
89.
90.